Related Experiment Videos
Velnacrine maleate improves delayed matching performance by aged monkeys
W J Jackson1, J J Buccafusco, A V Terry
1Department of Physiology and Endocrinology, Medical College of Georgia, Augusta 30912, USA.
Psychopharmacology
|June 1, 1995
Summary
Velnacrine maleate, an acetylcholinesterase inhibitor, improved short-term memory in aged macaques. This cognitive enhancement, particularly in long-delay trials, persisted for 24 hours post-administration.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Aging is associated with cognitive decline, particularly in memory function.
- Acetylcholinesterase inhibitors are a class of drugs investigated for treating cognitive impairments.
- Velnacrine maleate is an orally active acetylcholinesterase inhibitor with a prolonged action.
Purpose of the Study:
- To evaluate the efficacy of velnacrine in ameliorating age-related short-term memory decline in non-human primates.
- To assess the duration of velnacrine's effect on mnemonic function at 30 minutes and 24 hours post-administration.
Main Methods:
- Aged macaques (25-40 years) with memory impairment were trained on a delayed matching-to-sample (DMTS) task.
- Velnacrine was administered orally at doses of 1, 2, 4, and 6 mg/kg.
- Performance on DMTS, especially long-delay trials, was compared between velnacrine and placebo conditions.
Main Results:
- Velnacrine administration significantly improved performance on long-delay DMTS trials in aged macaques.
- Cognitive improvements were observed both 30 minutes and 24 hours after drug administration.
- Peak plasma concentrations of velnacrine were observed 30-60 minutes post-dosing, with detectable levels remaining at 6 hours.
Conclusions:
- Velnacrine maleate demonstrates significant potential in improving age-related memory deficits.
- The drug's efficacy in enhancing mnemonic function is sustained for at least 24 hours.
- Velnacrine represents a promising therapeutic agent for cognitive enhancement in aging populations.